骨髓增生异常综合征的靶向二代测序及突变与IPSS-R之间的预后交互作用
研究对179例原发性骨髓增生异常综合征(MDS)患者行27基因靶向二代测序,中位年龄73岁,按IPSS-R分层。82%检出至少一种突变,ASXL1、SETBP1、TP53为总生存风险因素,SRSF2、IDH2、CSF3R为无白血病生存风险因素;校正IPSS-R后TP53意义减弱,SF3B1有利影响不再明显,不良突变的影响在IPSS-R极低/低危组最明显。
要点
- 82%的MDS患者检出至少一种突变,23%携带三种及以上突变。
- ASXL1、SETBP1、TP53与总生存不良相关,SRSF2、IDH2、CSF3R与无白血病生存不良相关。
- 不良突变的生存影响在IPSS-R极低/低危患者中最明显。
核心结论
- 这些观察提示靶向二代测序可能有助于低危MDS的治疗决策。
研究设计与样本
- 采用27基因组合对179例原发性骨髓增生异常综合征患者进行二代测序,患者中位年龄73岁。
- 按修订版国际预后评分系统(IPSS-R)的风险分布为:极高危11%、高危18%、中危17%、低危38%、极低危16%。
主要发现
- 147例(82%)患者检出至少一种突变/变异,23%携带三种及以上突变/变异。
- 最常见的突变/变异包括ASXL1(30%)、TET2(25%)、SF3B1(20%)、U2AF1(16%)、SRSF2(16%)、TP53(13%)、RUNX1(11%)和DNMT3A(10%)。
- 中位随访30个月,记录到148例(83%)死亡和26例(15%)白血病转化。
- 多变量分析显示,ASXL1(HR 1.7,95%CI 1.2-2.5)、SETBP1(HR 4.1,95%CI 1.6-10.2)和TP53(HR 2.2,95%CI 1.3-3.4)为总生存的风险因素;SRSF2(HR 3.9,95%CI 1.5-10.2)、IDH2(HR 3.7,95%CI 1.2-11.4)和CSF3R(HR 6.0,95%CI 1.6-22.6)为无白血病生存的风险因素。
- 在多变量模型中加入年龄不影响上述结果,而校正IPSS-R后TP53突变/变异的显著性减弱(P=0.1);校正IPSS-R后SF3B1突变的有利生存影响不再明显。
关键数值与推荐
- 约41%的患者携带至少一种对总生存不良的突变/变异,约20%携带至少一种对无白血病生存不良的突变/变异。
- 突变/变异的数量未提供额外预后价值。
临床怎么用
- 作者认为,靶向二代测序可能有助于低危MDS的治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 27-gene panel was used for next-generation sequencing (NGS) in 179 patients (median age 73 years) with primary myelodysplastic syndromes (MDS); risk distribution according to the revised International Prognostic Scoring System (IPSS-R) was 11% very high, 18% high, 17% intermediate, 38% low and 16% very low. At least one mutation/variant was detected in 147 (82%) patients; 23% harbored three or more mutations/variants. The most frequent mutations/variants included ASXL1 (30%), TET2 (25%), SF3B1 (20%), U2AF1 (16%), SRSF2 (16%), TP53 (13%), RUNX1 (11%), and DNMT3A (10%). At a median follow up of 30 months, 148 (83%) deaths and 26 (15%) leukemic transformations were recorded. Multivariable analysis of mutations/variants identified ASXL1 (HR 1.7, 95% CI 1.2-2.5), SETBP1 (HR 4.1, 95% CI 1.6-10.2) and TP53 (HR 2.2, 95% CI 1.3-3.4) as risk factors for overall and SRSF2 (HR 3.9, 95% CI 1.5-10.2), IDH2 (HR 3.7, 95% CI 1.2-11.4), and CSF3R (HR 6.0, 95% CI 1.6-22.6) for leukemia-free survival. Addition of age to the multivariable model did not affect these results while accounting for IPSS-R weakened the significance of TP53 mutations/variants (P = .1). An apparently favorable survival impact of SF3B1 mutations was no longer evident after adjustment for IPSS-R. Approximately 41% and 20% of patients harbored at least one adverse mutation/variant for overall and leukemia-free survival, respectively. Number of mutations/variants did not provide additional prognostic value. The survival impact of adverse mutations was most evident in IPSS-R very low/low risk patients. These observations suggest that targeted NGS might assist in treatment decision-making in lower risk MDS.
引用
- Tefferi A, Lasho TL, Patnaik MM, et al. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. Am J Hematol. 2017. PMID: 28875545. doi:10.1002/ajh.24901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。